Overview
- By the end of day one, Corona Remedies was subscribed about 62% versus roughly 15% for Wakefit, with little QIB participation reported for either issue.
- Latest grey‑market signals diverged sharply, with Corona around Rs 262 per share (about 25% over the top band) and Wakefit near Rs 5 (about 3% over), per market trackers.
- Corona’s Rs 655.37 crore issue is a full offer for sale priced at Rs 1,008–1,062, while Wakefit seeks about Rs 1,288.89 crore via a fresh issue plus OFS at Rs 185–195.
- Anchor allocations were completed before launch, with Wakefit raising about Rs 580 crore from 33 anchors and Corona about Rs 194.85 crore from 15 anchors.
- Financials underscore the contrast: Corona posted FY25 PAT of Rs 149.43 crore, whereas Wakefit reported a FY25 net loss of about Rs 35 crore but a H1 FY26 profit of Rs 35.6 crore; subscriptions close December 10, allotments are expected December 11, and listing is tentatively set for December 15.